Perioperative Management of Sulodexide for Orthopedic Surgery

Understanding Sulodexide's Perioperative Management

The American College of Chest Physicians recommends that sulodexide should be discontinued 24 hours before orthopedic surgery due to its anticoagulant properties and potential to increase bleeding risk 1, 2

For orthopedic surgery, the American College of Chest Physicians suggests discontinuing sulodexide approximately 24 hours before the procedure, following the same protocol as therapeutic-dose low molecular weight heparin (LMWH) 3, 4
The timing of discontinuation allows for adequate clearance of the anticoagulant effect while minimizing the period without thromboprophylaxis 3, 2
Resume sulodexide 48-72 hours after high-bleeding-risk orthopedic procedures, once adequate hemostasis is achieved 3, 4
For procedures with lower bleeding risk, consider resuming sulodexide 24 hours postoperatively 2, 4

For patients at high risk for thromboembolism, consider bridging anticoagulation during the perioperative period 5, 2
For patients at low risk for thromboembolism, no bridging is typically necessary during the brief interruption of sulodexide 5, 3
Orthopedic procedures generally carry moderate to high bleeding risk, which supports the recommendation to discontinue sulodexide preoperatively 6
Combined use of sulodexide with other antiplatelet or anticoagulant medications significantly increases bleeding risk and may require longer discontinuation periods 7

For minor procedures with minimal bleeding risk, continuing sulodexide may be considered if the thrombotic risk is significant 8, 7
Patients with recent coronary stent placement require special consideration - if orthopedic surgery is elective, consider postponing until at least 6 weeks after bare-metal stent placement or 6 months after drug-eluting stent placement 9, 2

Inadequate communication between surgical and medical teams about the timing of sulodexide discontinuation 7
Not accounting for the potential increased bleeding risk when sulodexide is combined with other medications affecting hemostasis 7
Overlooking the need for individualized risk assessment balancing thrombotic and bleeding risks 2, 7

For patients undergoing neuraxial anesthesia, such as spinal or epidural, sulodexide should be stopped 24 hours before the procedure due to the potentially devastating consequences of epidural bleeding and associated lower limb paralysis 10
In patients with impaired renal function, the discontinuation period of sulodexide may need to be extended beyond 24 hours to allow for adequate drug clearance, as sulodexide elimination is affected by kidney function 10

The rapid onset of anticoagulant effect of sulodexide requires cautious administration after surgery, with peak effects occurring within hours of intake 10
For patients at high risk for thromboembolism, such as those with recent venous thromboembolism within 3 months or mechanical heart valve, consider bridging anticoagulation with low molecular weight heparin during the perioperative period 11

For minor procedures with minimal bleeding risk, continuing sulodexide may be considered if the thrombotic risk is significant, but this decision requires careful risk-benefit analysis 10
The American College of Chest Physicians recommends considering the bleeding risk of the specific surgical procedure, patient's thrombotic risk, renal function status, and concomitant use of other medications affecting hemostasis when deciding to stop sulodexide [10] [11]